ArticleResearch and reports in urology2016
Efficacy and safety evaluation of pentoxifylline associated with other antioxidants in medical treatment of Peyronie's disease: a case-control study.
Article in Research and reports in urology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 37 citations in OpenAlex.
- Contemporary Management Strategies for Peyronie's Disease: A Comprehensive Review.Research and reports in urology · 2026Review
- Article
- Oxidative Mechanism of Peyronie's Disease and Effectiveness of Pentoxifylline in the Therapeutic Management: A Narrative Review.Antioxidants (Basel, Switzerland) · 2025Review
- Acute Phase Peyronie's Disease: Where Do We Stand?Cureus · 2024Review
- Clinical Presentation of Peyronie's Disease: A Retrospective Study of 564 Cases.Diagnostics (Basel, Switzerland) · 2024Article
- Measurement of Oxidative Stress Index (OSI) in Penile Corpora Cavernosa and Peripheral Blood of Peyronie's Disease Patients: A Report of 49 Cases.Metabolites · 2024Article
- Role of Oxidative Stress in Peyronie's Disease: Biochemical Evidence and Experiences of Treatment with Antioxidants.International journal of molecular sciences · 2022Review
- Disappearance of Plaque Following Treatment with Antioxidants in Peyronie's Disease Patients-A Report of 3 Cases.Clinics and practice · 2022Article
- Patients with Peyronie's disease achieve complete plaque regression after multimodal treatment with antioxidants: a case series.Journal of medical case reports · 2022Article
- Full Regression of Peyronie's Disease Plaque Following Combined Antioxidant Treatment: A Three-Case Report.Antioxidants (Basel, Switzerland) · 2022Article
- Complete Plaque Regression in Patients with Peyronie's Disease After Multimodal Treatment with Antioxidants: A Report of 2 Cases.The American journal of case reports · 2022Article
- Trends in treatment of Peyronie's disease in adult men in the United States from 2008 to 2017-results from an encounter and claims database.International journal of impotence research · 2022Article
- Global Perspective on the Management of Peyronie's Disease.Frontiers in reproductive health · 2022Review
- Conservative Therapy for Peyronie's Disease: a Contemporary Review of the Literature.Current urology reports · 2021Review
- Minimally invasive therapies for Peyronie's disease: the current state of the art.Translational andrology and urology · 2020Review
- Patient's choice of health information and treatment modality for Peyronie's disease: a long-term assessment.International journal of impotence research · 2018Article
- Rationale of combination therapy with antioxidants in medical management of Peyronie's disease: results of clinical application.Research and reports in urology · 2017Article
- Recent Pathophysiological Aspects of Peyronie's Disease: Role of Free Radicals, Rationale, and Therapeutic Implications for Antioxidant Treatment-Literature Review.Advances in urology · 2017Review
- Peyronie's disease: a literature review on epidemiology, genetics, pathophysiology, diagnosis and work-up.Translational andrology and urology · 2016Review
- Oral therapy for Peyronie's disease, does it work?Translational andrology and urology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peyronie's disease (PD) is a chronic disorder involving the tunica albuginea surrounding the corpora cavernosa of the penis. A conservative treatment is indicated in the first stage of disease. The aim of this study was to assess the therapeutic impact and possible side effects of treatment with pentoxifylline (PTX) in combination with other antioxidants in 307 patients with early-stage PD. Patients were subdivided into three groups: A, B, and C. Both groups, A and B, comprising of 206 patients, underwent treatment, whereas Group C was the control group (n=101). Treatment lasted 6 months and included the following: Group A: PTX 400 mg twice a day + propolis 600 mg/d + blueberry 160 mg/d + vitamin E 600 mg/d + diclofenac 4% gel twice/a day + PTX 100 mg via perilesional penile injection/every other week (12 injections in all); Group B: the same treatment as Group A except for the penile PTX injections. After the 6-month treatment course, we obtained the following results: actual mean decrease in plaque volume -46.9% and -24.8% in Group A and B, respectively (P<0.0001); mean curvature reduction -10.1° and -4.8°, respectively (P,0.0001); resolution of pain in 67.6% and 67.2% of cases, respectively (P=0.961); recovery of normal penile rigidity in 56.09% and 23.5% of cases, respectively (P=0.005). After 6 months, progression of disease was observed in all patients belonging to Group C: plaque volume +123.3%; curvature +15.7°; no recovery of penile rigidity. The statistically significant results of our study show that multimodal treatment with PTX in association with other antioxidants and topical diclofenac is efficacious in treating early-stage PD. Furthermore, treatment proved to be more effective when PTX was administered both orally and by penile injection. No serious adverse effects occurred.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.